Two Denmark-based biotech companies, SNIPR Biome and TOOsonix, are experiencing their own set of ‘firsts’ with their respective technologies. SNIPR Biome, which specializes in CRISPR-based therapies, will undergo its first Phase 1 clinical trial on humans to evaluate the safety and effectiveness of reducing Escherichia coli (E. coli) colonization using their novel CRISPR-based therapeutics, SNIPR001.

TOOsonix centers around high-intensity focused ultrasound (HIFU) systems for various skin treatments. They will take aim at Basal Cell Carcinoma (BCC) in their first clinical study on the treatment with their System ONE-M device, a HIFU system capable of focusing energy in hyper-specific locations and depths to target affected skin areas. 

Denmark is one of the leading nations in Europe in the biotechnology industry. In 2021 alone, Danish biotech startups received $434 million in venture capital to further pioneer life-saving medicines used globally. This article will highlight two such companies’ momentous strides in extending Denmark’s biotech industry internationally.